Cellular proliferation in breast ductal infiltrating carcinoma. Correlation with clinical and histopathoiogical variables

Pathology Research and Practice

Volumn 193, Issue 10, 1997, Pages 683-688

  Aranda, F Ignacio ^a   Laforga, Juan B ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL MARINA ALTA   (Spain)

Author keywords

Breast neoplasm; Ki 67; Mitosis; PCNA; Proliferation

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST DUCT; CANCER GRADING; CELL PROLIFERATION; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS; MITOSIS INDEX; PROGNOSIS; TUMOR VOLUME;

EID: 0031414989     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(97)80027-1     Document Type: Article

References (46)

1. Aaltomaa S, Lipponen P, Syrjanen K (1992) Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nucelar antigen (PCNA) immunostaining. Anticancer Res 12: 1281-1286
2. Baak JPA (1990) Mitosis counting in tumors. Hum Pathol 21: 683-685
3. Barbareschi M, Girlando S, Mauri FM, Forti S, Eccher C, Mauri FA, Togni R, Palma PD, Doglioni C (1994) Am J Clin Pathol 102: 171-175
4. Barnes DM, Gillett CE (1995) Determination of cell proliferation. J Clin Pathol: Mol Pathol 48: M2-M5
5. Bergers E, Jannink I, van Diest PI, Cuesta MA, Meyer S, van Mourik JC, Baak JP (1997) The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol 28: 95-100
6. Biesterfeld S, Noll I, Noll E, Wohltmann D, Böcking A (1995) Mitotic frequency as a prognostic factor in breast cancer. Hum Pathol 26: 47-52
7. Brown DC, Gatter KC (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489-503
8. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 9: 359-377
9. Dawson AE, Norton JA, Weinberg DS (1990) Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 136: 1115-1124
10. van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans EC, Galen van CM, Kurver PHJ, Bellot SM, Fijnheer J, Gorp van LHM, Kwee WS, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Schipper MEI, Somsen JG, Willig AWPM, Ariens AT (1992) Reproducibility of mitosis counting in 2469 breast cancer specimens: results from multicenter morphometric mammary carcinoma project. Hum Pathol 23: 603-607
11. Donhuijsen K, Schmidt U, Hirche H, van Beuningen D, Budach V (1990) Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol 21: 709-714
12. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410
13. Frierson HF Jr. (1993) Immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinomas: comparison with clinical and pathological variables. Mod Pathol 6: 290-294
14. Gasparini G, Meli S, Pozza F, Cazzavillan S, Bevilacqua P (1992) PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma. Growth Regul 2: 145-150
15. Gee JM, Douglas-Jones A, Hepburn P, Sharma AK, McClelland RA, Ellis IO, Nicholson RI (1995) A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J Pathol 177: 285-293
16. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715
17. Gerdes J, Becker MHG, Key G, Cattoretti G (1992) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 168: 85-86
18. Gillet CE, Barnes DM, Camplejohn RS (1993) Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma. J Clin Pathol 46: 1126-1128
19. Going JJ (1994) Efficiently estimated histologic cell counts. Hum Pathol 25: 333-336
20. Haapasalo H, Pesonen E, Collan Y (1989) Volume corrected mitotic index (M/V-Index). The standard of mitotic activity in neoplasms. Pathol Res Pract 185: 551-554
21. Hall PA, Levison DA, Woods AL, Yu C C-V, Lellok DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294
22. Jannink I, van Diest PJ, Baak JP (1995) Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol 26: 1086-1092
23. Jensen V, Ladekarl M (1995) Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. J Clin Pathol 48: 429-432
24. Keshgegian AA, Cnaan A (1995) Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB1. Am J Clin Pathol 104: 42-49
25. Kujari HP, Collan YU, Atkin NB (1994) Use of the mitotic counts for the prognosis and grading of breast cancer. Method evaluation study. Pathol Res Pract 190: 593-599
26. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla Palma P, Barbareschi M (1992) PCNA and Ki67 expression in breast carcinoma: correlation with clinical and biological variables. J Clin Pathol 45: 416-419
27. Leong A S-Y, Vinyuvat S, Suthipintawong C, Milios J (1995) A comparative study of cell proliferation markers in breast carcinomas. J Clin Pathol: Mol Pathol 48: M83-M87
28. Linden MD, Torres FX, Kubus J, Zarbo RJ (1992) Clinical application of morphologic and immunocytochemical assessments of cell proliferation (Editorial). Am J Clin Pathol 97 (suppl 1): s4-s13
29. Mascarel I de, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM (1995) Immunohistochemical analysis of estrogen receptors in 938 breast carcnomas. Concordance with biochemical assay and prognostic significance. Appl Immunohistochem 3: 222-231
30. Mauri FA, Girlando S, Palma PD, Buffa G, Perrone G, Doglioni C, Kreipe H, Barbareschi M (1994) Ki-67 antibodies (Ki-S5, MIB-1, and Ki-67) in breast carcinomas. A brief quantitative comparison. Appl Immunohistochem 2: 171-176
31. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721
32. McCormick D, Chong H, Hobbs C, Datta C, Hall PA (1993) Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 22: 355-360
33. Mohammed RJ, Lakatua DJ, Haus E, Yasmineh WJ (1986) Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer 58: 1076-1081
34. Ogata K, Kurki P, Celis JE, Nakamura RM, Tan EM (1987) Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication. Exp Cell Res 168: 475-486
35. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JFR, Blarney RW, Ellis IO (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71: 146-149
36. Quinn CM, Wright NA (1990) The clinical assessment of proliferation and growth in human tumours: evaluation of methods and application as prognostic variables. J Pathol 160: 93-102
37. Schimmelpenning H, Eriksson ET, Franzen B, Zetterberg A, Auer GU (1993) Prognostic value of the combined assessment of proliferating cell nuclear antigen immunostaining and nuclear DNA content in invasive human mammary carcinomas. Virchows Arch A Pathol Anat Histopathol 423: 273-279
38. Schmitt FC, Ferreira MP (1995) MIB-1 is a suitable marker of proliferative activity in formalin-fixed, paraffin-embedded sections of breast cancer. Int J Surg Pathol 2: 287-294
39. Siitonen S, Isola JJ, Rantala IS, Helin H (1993) Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nucelar antigen monoclonal antibody and automated image analysis. Am J Clin Pathol 99: 226-231
40. Simpson JF, Dutt PL, Page DL (1992) Expression of mitosis per thousand cells and cell density in breast carcinomas: a proposal. Hum Pathol 23: 608-611
41. Tahan SR, Neuberg DS, Dieffenbach A, Yacoub L (1993) Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 71: 3552-3559
42. Thomas M, Noguchi M, Kitagawa H, Kinoshita K, Miyazaki I (1993) Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 46: 525-528
43. Visscher DW, Wykes S, Kubus J, Crissman JD (1992) Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer. Breast Cancer Res Treat 22: 111-118
44. Waseem NH, Lane DP (1990) Monoclonal antibody analysis of proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 96: 121-129
45. Weidner N, Moore II DH, Vartanian R (1994) Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 25: 337-342
46. WHO (1982) The Word Health Orgatization histological Typing of breast tumors, Second Edition. Am J Clin Pathol 78: 806-816